{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T06:37:21Z","timestamp":1784011041937,"version":"3.55.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Premature infants are particularly vulnerable to complications such as bronchopulmonary dysplasia (BPD). Although systemic steroids have been used for some time, no effective alternative treatments have emerged. This has led clinicians to investigate various dosing regimens and discuss the necessity of revising systemic steroid dosages. This study aims to evaluate the effectiveness and safety of two different doses of systemic dexamethasone use in treating BPD in premature infants born at or below 30 weeks of gestation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective review was conducted on hospital records of premature infants admitted to the Neonatal Intensive Care Unit of Izmir Private Medicalpark Hospital for a 6-year period. In the first 2 years of these 6 years, as historical controls, infants with evolving BPD had received dexamethasone treatment according to the DART protocol, while the ones born in the last 4 years received enhanced low-dose treatment. Data collected included demographic characteristics, risk factors for preterm birth, duration and way of oxygen support, prematurity-related complications, systemic dexamethasone doses, and mortality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 368 infants analyzed in the study, 265 had received systemic enhanced low dose dexamethasone, while 103 had received low dose dexamethasone treatment. Baseline characteristics including gestational age, birth weights, and RDS severity were similar among groups The study found that a cumulative dose of 1.35\u2005mg\/kg of systemic dexamethasone (enhanced low dose) is both safe and more effective than standard low dose dexamethasone (DART protocole) therapy in the management of BPD. The DART group required significantly longer invasive and non-invasive ventilatory support compared to the enhanced low-dose group. By the 36th gestational week, a higher proportion of infants in the enhanced low-dose group were free from oxygen support. The enhanced low-dose group also had a higher extubation success rate. Dexamethasone -related side effects were minimal, with only two cases of hypertension and one of interventricular septal hypertrophy in the enhanced low dose group, and one case of hypertension in the DART group, all resolving over time.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our study suggests that an enhanced low-dose dexamethasone regimen (1.35\u2005mg\/kg) may offer superior respiratory outcomes compared to the conventional DART protocol without a significant increase in short-term adverse effects.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2025.1603308","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T05:28:37Z","timestamp":1754544517000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Enhanced vs. standard low dose dexamethasone treatment on respiratory outcomes of preterm infants with bronchopulmonary dysplasia"],"prefix":"10.3389","volume":"13","author":[{"given":"Sezgin","family":"Gunes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzan","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Bozkurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Begum","family":"Cezayir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arda","family":"Bozgul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"Gonulal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Yekta","family":"Oncel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.4274\/forbes.galenos.2021.41636","article-title":"Less invasive surfactant applications in newborns","volume":"3","author":"Yurttutan","year":"2022","journal-title":"Forbes J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1164\/ajrccm.163.7.2011060","article-title":"Bronchopulmonary dysplasia","volume":"163","author":"Jobe","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1038\/s41372-021-01083-w","article-title":"Postnatal steroid management in preterm infants with evolving bronchopulmonary dysplasia","volume":"41","author":"Htun","year":"2021","journal-title":"J Perinatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00408-018-0084-z","article-title":"Recent advances in bronchopulmonary dysplasia: pathophysiology, prevention, and treatment","volume":"196","author":"Hwang","year":"2018","journal-title":"Lung"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1542\/peds.2006-2250","article-title":"Early neonatal hydrocortisone: study rather than treat","volume":"118","author":"Hallman","year":"2006","journal-title":"Pediatrics"},{"key":"B6","doi-asserted-by":"publisher","first-page":"F334","DOI":"10.1136\/adc.2006.106583","article-title":"Are postnatal steroids ever justified to treat severe bronchopulmonary dysplasia?","volume":"92","author":"Eichenwald","year":"2007","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"B7","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1542\/peds.107.2.413","article-title":"Postnatal glucocorticoids in very preterm infants: \u201cthe good, the bad, and the ugly?\u201d","volume":"107","author":"Th\u00e9baud","year":"2001","journal-title":"Pediatrics"},{"key":"B8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/j.1440-1754.2007.01000.x","article-title":"Total steroid dose given to ventilated newborn infants with chronic lung disease","volume":"43","author":"Jones","year":"2007","journal-title":"J Paediatr Child Health"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJM199904013401304","article-title":"Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia","volume":"340","author":"Cole","year":"1999","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/00130478-200010000-00009","article-title":"Meter-dosed, inhaled beclomethasone initiated at birth to prevent bronchopulmonary dysplasia","volume":"1","author":"Zimmerman","year":"2000","journal-title":"Pediatr Crit Care Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1159\/000515950","article-title":"Postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia","volume":"118","author":"Doyle","year":"2021","journal-title":"Neonatology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/archdischild-2023-326254","article-title":"Hydrocortisone in very preterm neonates for BPD prevention: meta-analysis and effect size modifiers","volume":"109","author":"De Luca","year":"2024","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"B13","doi-asserted-by":"publisher","first-page":"CD010941","DOI":"10.1002\/14651858.CD010941.pub2","article-title":"Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants","volume":"2017","author":"Onland","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"B14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1542\/peds.2004-2843","article-title":"Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial","volume":"117","author":"Doyle","year":"2006","journal-title":"Pediatrics"},{"key":"B15","doi-asserted-by":"publisher","first-page":"S138","DOI":"10.5152\/TurkPediatriArs.2018.01814","article-title":"Turkish neonatal society guideline on prevention and management of bronchopulmonary dysplasia","volume":"53","author":"Arsan","year":"2018","journal-title":"Turk Pediatr Arch"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1001\/jama.2017.2692","article-title":"Association between early low-dose hydrocortisone therapy in extremely preterm neonates and neurodevelopmental outcomes at 2 years of age","volume":"317","author":"Baud","year":"2017","journal-title":"JAMA"},{"key":"B17","doi-asserted-by":"publisher","first-page":"CD001145","DOI":"10.1002\/14651858.CD001145.pub3","article-title":"Late (>7 days) postnatal corticosteroids for chronic lung disease in preterm infants","volume":"5","author":"Doyle","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"B18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.5005\/jp-journals-11002-0009","article-title":"Let\u2019s talk about Dex: when do the benefits of dexamethasone for prevention of bronchopulmonary dysplasia outweigh the risks?","volume":"1","author":"Nguyen","year":"2022","journal-title":"Newborn"},{"key":"B19","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/ppe.13123","article-title":"Inter-hospital variations in the respiratory outcomes of very and extremely pre-term infants: a cohort study in Japan","volume":"38","author":"Mimura","year":"2024","journal-title":"Paediatr Perinat Epidemiol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e206826","DOI":"10.1001\/jamapediatrics.2020.6826","article-title":"Assessment of postnatal corticosteroids for the prevention of bronchopulmonary dysplasia in preterm neonates","volume":"175","author":"Ramaswamy","year":"2021","journal-title":"JAMA Pediatr"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1261316","DOI":"10.3389\/fped.2023.1261316","article-title":"Comparing low-dose (DART) and enhanced low-dose dexamethasone regimens in preterm infants with bronchopulmonary dysplasia","volume":"11","author":"Al-taweel","year":"2023","journal-title":"Front Pediatr"},{"key":"B22","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1542\/peds.2007-2258","article-title":"Effects of higher versus lower dexamethasone doses on pulmonary and neurodevelopmental sequelae in preterm infants at risk for chronic lung disease: a meta-analysis","volume":"122","author":"Onland","year":"2008","journal-title":"Pediatrics"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/eme06080","article-title":"Very low-dose dexamethasone to facilitate extubation of preterm babies at risk of bronchopulmonary dysplasia: the MINIDEX feasibility RCT","volume":"6","author":"Yates","year":"2019","journal-title":"NIHR J Libr"},{"key":"B24","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1542\/peds.2008-0016","article-title":"Finding the optimal postnatal dexamethasone regimen for preterm infants at risk of bronchopulmonary dysplasia: a systematic review of placebo-controlled trials","volume":"123","author":"Onland","year":"2009","journal-title":"Pediatrics"},{"key":"B25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jpeds.2019.04.047","article-title":"Randomized trial of 42-day compared with 9-day courses of dexamethasone for the treatment of evolving bronchopulmonary dysplasia in extremely preterm infants","volume":"211","author":"Marr","year":"2019","journal-title":"J Pediatr"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e3523","DOI":"10.4212\/cjhp.3523","article-title":"Dexamethasone use to reduce mechanical ventilation and bronchopulmonary dysplasia in the neonatal intensive care unit","volume":"77","author":"Padam","year":"2024","journal-title":"Can J Hosp Pharm"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1056\/NEJMoa030813","article-title":"Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity","volume":"350","author":"Yeh","year":"2004","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"F46","DOI":"10.1136\/adc.2003.048389","article-title":"Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: a systematic review","volume":"90","author":"Doyle","year":"2005","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"B29","doi-asserted-by":"publisher","first-page":"CD013271","DOI":"10.1002\/14651858.CD013271.pub2","article-title":"Corticosteroids for the prevention and treatment of bronchopulmonary dysplasia: an overview of systematic reviews","volume":"2024","author":"van de Loo","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"B30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1001\/jamapediatrics.2022.3955","article-title":"Off-label use of postnatal corticosteroids for bronchopulmonary dysplasia in preterm infants: a meta-analysis","volume":"177","author":"Been","year":"2023","journal-title":"JAMA Pediatr"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1603308\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T05:28:38Z","timestamp":1754544518000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1603308\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":30,"alternative-id":["10.3389\/fped.2025.1603308"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1603308","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"article-number":"1603308"}}